Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts. Moderna shares surged Wednesday after the company also announced another $3 billion share buyback plan. Moderna’s vaccine sales in the second quarter represent a drop from the nearly $6 billion that the vaccine brought in during the year’s first quarter, when a virus surge through the United States pushed …
Moderna Inc.’s first-quarter sales tripled from a year ago on the back of its Covid-19 vaccine. The biotechnology company’s revenue topped $6 billion in the period ended March 31, beating analyst expectations, driven almost entirely by sales of its mRNA-based vaccine. The Cambridge, Mass.-based company’s so-called Spikevax shot received full approval from the Food and Drug Administration in January, making …
